Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

4(57.1%)

Phase 2

3(42.9%)

7Total

Phase 4(4)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02705508Phase 2Unknown

PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma

Role: collaborator

NCT01677208Phase 4Completed

Danhong Injection in the Treatment of Acute Ischemic Stroke

Role: collaborator

NCT02176395Phase 4Completed

Multi-"Omics" Research of Danhong Injection to Treat Acute Ischemic Stroke

Role: collaborator

NCT03091634Phase 2Completed

The Efficacy and Safety of the Xue-Fu-Zhu-Yu Capsule in Treatment of Qi Stagnation and Blood Stasis Syndrome.

Role: collaborator

NCT02986451Phase 2Withdrawn

Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

Role: collaborator

NCT02007187Phase 4Completed

Danhong Injection in the Treatment of Unstable Angina Pectoris

Role: collaborator

NCT01681316Phase 4Completed

Danhong Injection in the Treatment of Chronic Stable Angina

Role: collaborator

All 7 trials loaded